Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-11-13
1999-10-05
Patterson, Jr., Charles L.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241341, 424 943, 435236, 435 697, 536 234, A61K 3942, A61K 3843
Patent
active
059619732
ABSTRACT:
This invention pertains to biocatalysts that are specifically targeted to bind pathogens, such as viruses, and to degrade components of pathogens in order to abrogate their pathogenicity, and to methods of preventing or treating infection by pathogenic organisms. The biocatalysts comprise a binding agent which specifically binds a surface component of a pathogen, for instance the gp120 viral coat protein of the Human Immunodeficiency Virus, and a catalytic moiety which degrades a component of the pathogen so that its pathogenicity is abrogated. The binding agent and the catalytic moiety are linked by chemical linkers or genetic engineering techniques.
REFERENCES:
patent: 4671958 (1987-06-01), Rodwell et al.
Berger et al., "CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and its active against cels expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses" Proceedings of the National Acedemy of Sciences, vol. 86, No. 23, pp. 9539-9543 (Dec. 1989).
Capon et al., "Designing CD4 immunoadhesins for AIDS therapy" Nature, vol. 337, pp. 525-531 (Feb. 9, 1989).
Chaudhary et al., "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein" Nature, vol. 335, pp. 369-372, Sep. 22, (1988).
Clements et al., "The V3 Loop of the HIV-1 and HIV-2 Surface Glycoproteins Contain Proteolytic Cleavage Sites: A Possible Function in Viral Fusion?" AIDS Research and Human Retroviruses, vol. 7, No. 1, pp. 3-16 (1991).
Degen et al., "Characterization of the Complementary Deoxyribonulceic Acid and Gene Coding for Human Prothrombin" Biochemistry, vol. 22, pp. 2087-2097 (1983).
Pennica et al., Cloning and Expression of Human Tissue-type Plasminogen Activator of cDNA in E. coli Nature, vol. 201, pp. 214-221 (Jan. 20, 1983).
Poulin et al., "Several CD4 Domains Can Play a Role in Human Immunodeficiency Virus Infection of Cells" Journal of Virology, vol. 65, No. 9, pp. 4893-4901, Sep. 1991.
Schnee et al., "Construction and expression of recombinant antibody-targeted plasminogen activator" Proceedings of the National Academy of Sciences, vol. 84, pp. 6904-6903, Oct. 1987.
Till et al., "HIV-Infected Cells Are Killed by rCD4-Ricin A Chain" Science, vol. 242, pp. 1166-1168, Nov. 25, 1988.
Traunecker et al., "Highly efficient neutralization of HIV with recombinant CD4- immunoglobulin molecules" Nature Letters to Nature, vol. 339, pp. 68-71, May 4, 1989.
DeConti, Jr., Esq Giulio A.
Patterson Jr. Charles L.
LandOfFree
Pathogen-targeted biocatalysts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pathogen-targeted biocatalysts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pathogen-targeted biocatalysts will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1168331